Last $28.06 USD
Change Today -0.33 / -1.16%
Volume 251.0K
BRLI On Other Exchanges
Symbol
Exchange
Berlin
NASDAQ GS
As of 8:10 PM 09/30/14 All times are local (Market data is delayed by at least 15 minutes).

bio-reference labs inc (BRLI) Snapshot

Open
$28.48
Previous Close
$28.39
Day High
$28.60
Day Low
$27.93
52 Week High
11/26/13 - $37.97
52 Week Low
01/6/14 - $24.13
Market Cap
778.0M
Average Volume 10 Days
173.6K
EPS TTM
$1.43
Shares Outstanding
27.7M
EX-Date
--
P/E TM
19.6x
Dividend
--
Dividend Yield
--
Current Stock Chart for BIO-REFERENCE LABS INC (BRLI)

bio-reference labs inc (BRLI) Related Bloomberg News

View More Bloomberg News

bio-reference labs inc (BRLI) Related Businessweek News

No Related Businessweek News Found

bio-reference labs inc (BRLI) Details

Bio-Reference Laboratories, Inc. provides clinical laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases in New Jersey, New York, Maryland, Massachusetts, Texas, and Ohio. The company offers chemical diagnostic tests, such as blood and urine analysis; blood chemistry; hematology services; serology; radio-immuno analysis; toxicology, including drug screening; pap smears; tissue pathology comprising biopsies; and other tissue analysis, as well as cancer cytogenetic testing, genetic testing, and cytology testing services. It focuses on esoteric testing, molecular diagnostics, anatomical pathology, genetics, women’s health, and correctional health care services. The company also operates a clinical knowledge management service unit, which uses customer data from laboratory results, pharmaceutical data, claims data, and other data sources to provide administrative and clinical decision support systems; and a Web-based connectivity portal solution for laboratories and physicians. It serves physicians, geneticists, hospitals, clinics, and correctional and other health facilities. The company was founded in 1981 and is headquartered in Elmwood Park, New Jersey.

3,338 Employees
Last Reported Date: 01/13/14
Founded in 1981

bio-reference labs inc (BRLI) Top Compensated Officers

Founder, Chairman, Chief Executive Officer, P...
Total Annual Compensation: $1.2M
Chief Financial Officer, Chief Accounting Off...
Total Annual Compensation: $449.2K
Chief Operating Officer, Executive Vice Presi...
Total Annual Compensation: $449.9K
Compensation as of Fiscal Year 2013.

bio-reference labs inc (BRLI) Key Developments

The State Department of Public Health Issues Cease and Desist Order Against BioReference Laboratories Inc

The state Department of Public Health (DPH) issued a cease and desist order against BioReference Laboratories Inc. of New Jersey for operating the unlicensed blood collection centers in Fairfield, Ansonia, Milford, New London, Norwich, Waterbury, Wallingford and North Stonington. The order said BioReference has a licensed clinical laboratory at 27 Hospital Ave. in Danbury, but that it opened the other labs before receiving a license or certificate to operate them. In the order, BioReference agreed to stop operations at those locations until it obtains a license or certificate. The company, which bills itself on its website as the third large chain of full-service clinical diagnostic labs in the U.S., admitted in the order that it had operated the eight labs without a license. It also agreed that if it does not comply with the cease and desist order, that would be sufficient grounds for DPH to suspend its license to operate in Connecticut.

Bio-Reference Laboratories Inc. Announces Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended July 31, 2014

Bio-Reference Laboratories Inc. announced unaudited consolidated earnings results for the third quarter and nine months ended July 31, 2014. The company recorded revenues of $222,053,000 in the third quarter, the highest recorded revenues in a quarter, representing an increase of 20% over the $185,427,000 recorded in the third quarter of 2013. Operating income was $27,871,000, up 11% from operating income of $25,059,000 reported last year. Net income after taxes was $15,250,000, resulting in diluted earnings per share of $0.55, up from net income after taxes of $14,701,000 and diluted earnings per share of $0.53, increases of 4% and 4%, respectively. Income before taxes was $27,358,000 against $25,755,000 reported last year. Cash flow was $7,700,000 is almost 3x that of the previous quarter, almost double the cash flow of the same quarter last year. Revenues for the first nine-months of fiscal 2014 increased to $604,688,000, an increase of 16% over the revenues for the first nine months of fiscal 2013 of $523,136,000. Operating income was $52,630,000, a decrease of 14% from operating income of $61,527,000 reported last year. Net income after taxes was $28,477,000, resulting in an diluted earnings per share of $1.02, a decrease of 18% from the first nine-months of fiscal 2013 net income after taxes of $34,704,000, which resulted in an diluted earnings per share of $1.25. Cash flow from operations was a positive $7,505,000 compared to a positive $16,975,000 in the prior year same period. Income before taxes was $50,852,000 against $61,324,000 reported last year.

Bio-Reference Laboratories Inc. to Report Q3, 2014 Results on Aug 27, 2014

Bio-Reference Laboratories Inc. announced that they will report Q3, 2014 results on Aug 27, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BRLI:US $28.06 USD -0.33

BRLI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Alliance HealthCare Services Inc $22.61 USD -0.97
Genomic Health Inc $28.31 USD -1.10
Myriad Genetics Inc $38.57 USD -0.30
RadNet Inc $6.62 USD -0.16
Sequenom Inc $2.97 USD -0.05
View Industry Companies
 

Industry Analysis

BRLI

Industry Average

Valuation BRLI Industry Range
Price/Earnings 20.0x
Price/Sales 1.0x
Price/Book 2.6x
Price/Cash Flow 12.3x
TEV/Sales 0.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BIO-REFERENCE LABS INC, please visit www.bioreference.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.